News and commentary from the world of gastroenterology and hepatology ...

The ‘TL1A’ messenger protein of the immune system triggers gut-to-bone marrow reaction, increasing the colorectal cancer risk ...

Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in ...

Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.

Flare-ups can occur at any time and are often triggered by various factors, including stress, certain foods, infections, use ...

A chain of immune reactions in the gut—driven by a key signaling protein and a surge of white blood cells from the bone ...

A "living glue" used by barnacles to attach to underwater surfaces could also seal gut wounds caused by inflammatory bowel ...

For decades, patients with inflammatory bowel disease have reported a familiar and frustrating pattern: periods of intense stress are often followed by worsening symptoms or full-blown disease flares.

In the treatment of inflammatory bowel disease, synthetic mucus gels can be used to deliver monoclonal antibodies without inducing broad immunosuppression.

German drugmaker Boehringer Ingelheim will license an experimental inflammatory bowel disease treatment from China's Simcere ...

A chain of immune reactions in the gut - driven by a key signaling protein and a surge of white blood cells from the bone marrow - may help explain ...

Inflammatory bowel disease, or IBD, has become an epidemic in urban cities. Here are the signs to watch out for and when to seek medical treatment.